Proteostasis files $86M IPO; Novartis publishes Cosentyx studies;

> Cambridge, MA-based Proteostasis Therapeutcs filed for an $86 million IPO. Filing

> Results of the MEASURE 1 and MEASURE 2 Phase III studies for Novartis's Cosentyx (secukinumab) in ankylosing spondylitis were published in The New England Journal of Medicine. Release

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.